Physician profile
Mark B Effron
NPI 1598139362
$4,637.94
in general payments reported to CMS, 2019-2025
18 companies · $665 in 2025
The $665 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.77 · 2020: $20.75 · 2021: $402 · 2022: $844 · 2023: $1,367 · 2024: $1,274 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,690 · Travel and Lodging: $616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,690.23 |
| Travel and Lodging | $616.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Research & Development, LLC | $772.95 | 2023 | |
| Boston Scientific Corporation | $652.77 | 2022-2024 | Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd |
| Novartis Pharmaceuticals Corporation | $549.94 | 2021-2025 | |
| Amgen INC. | $509.59 | 2021-2025 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $380.85 | 2023-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $332.68 | 2021-2024 | Xarelto |
| Novo Nordisk INC | $307.45 | 2024-2025 | Wegovy, Ozempic |
| Kestra Medical Technology Services, INC. | $224.91 | 2022-2025 | Assure Wcd |
| Pfizer INC. | $208.40 | 2019-2025 | |
| Biosense Webster, INC. | $146.82 | 2024 | Carto 3 |
| Astrazeneca Pharmaceuticals Lp | $139.20 | 2020-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $121.36 | 2021-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $89.86 | 2022 | |
| Medtronic, INC. | $85.15 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.55 | 2022-2023 | Jardiance |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $29.42 | 2021 | |
| Livanova USA, INC. | $22.05 | 2022 | |
| Janssen Scientific Affairs, LLC | $15.99 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Effron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.